Compare EHI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EHI | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 160.5M |
| IPO Year | 2003 | 2010 |
| Metric | EHI | HURA |
|---|---|---|
| Price | $5.38 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 165.3K | ★ 178.6K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.36 | $0.41 |
| 52 Week High | $6.61 | $3.43 |
| Indicator | EHI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 20.26 | 52.74 |
| Support Level | N/A | $2.04 |
| Resistance Level | $6.03 | $2.24 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 0.03 | 70.83 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.